BIOHLDG 0179 QUARTERLY REPORT 30 SEPT 2018
Quarterly Report Review:
收入与去年同期相比增加43%。
马来西亚占总收入最大，第二是印尼，第三是中国。
制造和销售保健品业务收入与去年同期相比增加主要是保健品销售增加尤其在马来西亚，而印尼和中国销售保持。
零售药店业务收入与去年同期相比增加主要是注册的零售药店增加。
该集团预计客户量将会持续上升并会带动销售额提升。
该集团会开设新店和收购其它药店来扩大市场份额。
该集团仍然会在中国地区继续销售产品并推广Bioalpha的清真认证产品。
该集团在印尼与伙伴合作并在当地工厂制造保健品，缩短产品的注册程式。
该集团预计印尼的收入将会逐渐增加。
Reference Price:
26.11.2018
Price: RM 0.24
Rolling EPS: RM 0.0166
PE: 14.46
NTA: RM 0.1779
Price/NTA: 1.35
PE*Price/NTA: 19.51
Undervalued: RM 0.19
Fair Value: RM 0.255
Overvalued: RM 0.38
Disclaimer:
The information contained in this research is based on data obtained from sources believed to be reliable. However, the data and/or sources have not been independently verified and as such, no representation, express or implied, is made as to the accuracy, adequacy, completeness or reliability of the info or opinions in the research.
Accordingly, neither 以牛攻熊 nor any of its related companies and associates nor person connected to it accept any liability whatsoever for any direct, indirect or consequential losses (including loss of profits) or damages that may arise from the use or reliance on the info or opinions in this publication. Any information, opinions or recommendations contained herein are subject to change at any time without prior notice. 以牛攻熊 has no obligation to update its opinion or the information in this research.
Investors are advised to make their own independent evaluation of the info contained in this research and seek independent financial, legal or other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this research. Nothing in this research constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise represent a personal recommendation to you.
This research is being supplied to you on a strictly confidential basis solely for your information and is made strictly on the basis that it will remain confidential. All materials presented in this research, unless specifically indicated otherwise, is under copyright to 以牛攻熊. This research and its contents may not be reproduced, stored in a retrieval system, redistributed, transmitted or passed on, directly or indirectly, to any person or published in whole or in part, or altered in any way, for any purpose.
This research may provide the addresses of, or contain hyperlinks to, websites. 以牛攻熊 takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to 以牛攻熊 own site material) are provided solely for your convenience. The information and the content of the linked site do not in any way form part of this research. Accessing such website or following such link through the research or 以牛攻熊 site shall be at your own risk.
收入与去年同期相比增加43%。
马来西亚占总收入最大，第二是印尼，第三是中国。
制造和销售保健品业务收入与去年同期相比增加主要是保健品销售增加尤其在马来西亚，而印尼和中国销售保持。
零售药店业务收入与去年同期相比增加主要是注册的零售药店增加。
该集团预计客户量将会持续上升并会带动销售额提升。
该集团会开设新店和收购其它药店来扩大市场份额。
该集团仍然会在中国地区继续销售产品并推广Bioalpha的清真认证产品。
该集团在印尼与伙伴合作并在当地工厂制造保健品，缩短产品的注册程式。
该集团预计印尼的收入将会逐渐增加。
Reference Price:
26.11.2018
Price: RM 0.24
Rolling EPS: RM 0.0166
PE: 14.46
NTA: RM 0.1779
Price/NTA: 1.35
PE*Price/NTA: 19.51
Undervalued: RM 0.19
Fair Value: RM 0.255
Overvalued: RM 0.38
Disclaimer:
The information contained in this research is based on data obtained from sources believed to be reliable. However, the data and/or sources have not been independently verified and as such, no representation, express or implied, is made as to the accuracy, adequacy, completeness or reliability of the info or opinions in the research.
Accordingly, neither 以牛攻熊 nor any of its related companies and associates nor person connected to it accept any liability whatsoever for any direct, indirect or consequential losses (including loss of profits) or damages that may arise from the use or reliance on the info or opinions in this publication. Any information, opinions or recommendations contained herein are subject to change at any time without prior notice. 以牛攻熊 has no obligation to update its opinion or the information in this research.
Investors are advised to make their own independent evaluation of the info contained in this research and seek independent financial, legal or other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this research. Nothing in this research constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise represent a personal recommendation to you.
This research is being supplied to you on a strictly confidential basis solely for your information and is made strictly on the basis that it will remain confidential. All materials presented in this research, unless specifically indicated otherwise, is under copyright to 以牛攻熊. This research and its contents may not be reproduced, stored in a retrieval system, redistributed, transmitted or passed on, directly or indirectly, to any person or published in whole or in part, or altered in any way, for any purpose.
This research may provide the addresses of, or contain hyperlinks to, websites. 以牛攻熊 takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to 以牛攻熊 own site material) are provided solely for your convenience. The information and the content of the linked site do not in any way form part of this research. Accessing such website or following such link through the research or 以牛攻熊 site shall be at your own risk.
Comments
Post a Comment